CircuLex High-Sensitivity CRP ELISA Kit

CircuLex High-Sensitivity CRP ELISA Kit.



The CircuLex High-Sensitivity CRP ELISA Kit is used for the quantitative measurement of Human C-reactive protein (CRP) in serum, plasma and other biological media. It can be used for 96 Assays.

Target: CRP
Product Type: ELISA Kit
Size: 96 Assays
Application: ELISA
Research Area / Disease: Metabolism
Sensitivity: better than 28.6 pg/mL of sample.
Measurement Range: Dilution factors need to be taken into consideration in calculating the Human CRP concentration.Results exceeding Human CRP level of 9.5 μg/ml should be repeated with diluted samples.
Regulatory Statement: For Research Use Only. Not for use in diagnostic procedures.


  • Microplate
  • 10X Wash Buffer
  • Dilution Buffer
  • Human CRP Standard
  • HRP conjugated Detection Antibody
  • Substrate Reagent
  • Stop Solution


  1. Ortega E et al. Aquatic exercise improves the monocyte pro- and anti-inflammatory cytokine production balance in fibromyalgia patients. Scand J Med Sci Sports. 22, 104-12 (2012)
  2. Pascale S et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 119, 3595-603 (2012),
  3. Hiura K et al. The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis. Rheumatol Int. 33, 2309-14 (2013),
  4. Umeno A et al. Singlet oxygen induced products of linoleates, 10- and 12-(Z,E)-hydroxyoctadecadienoic acids (HODE), can be potential biomarkers for early detection of type 2 diabetes. PLoS One. 8, e63542 (2013)
  5. Yamaguchi Y et al. Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals. Thromb Res. 132, 263-70 (2013)
  6. Nakamura T et al. Role of high-sensitivity C-reactive protein in the differentiation of benign and malignant soft tissue tumors. Anticancer Res. 34, 933-6 (2014),
  7. Shindo A et al. Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability. PLoS One. 9, e100045 (2014),
  8. Yilmaz Ö et al. The effect of prolactin levels on MPV in women with PCOS. Clin Endocrinol. 82, 747-52 (2015)
  9. Fuchiwaki Y et al. New approach to a practical quartz crystal microbalance sensor utilizing an inkjet printing system. Sensors. 14, 20468-79 (2014)
  10. Yilmaz & Ouml; et al. Association between red blood cell distribution width and polycystic ovary syndrome. Endocr Res. 1-7 (2014)
  11. Wada H et al. VEGF-C and Mortality in Patients With Suspected or Known Coronary Artery Disease. J Am Heart Assoc. 7, e010355 (2018)
  12. Goto M et al. Aging-associated latent herpes viral infection in normal Japanese individuals and patients with Werner syndrome. Intractable Rare Dis Res. 7, 229-235 (2018)
  13. Umeno A, Yoshida Y. Utility of hemoglobin A1c in detecting risk of type 2 diabetes: comparison of hemoglobin A1c with other biomarkers. J Clin Biochem Nutr. 65, 59-64 (2019)


  1. Westhuyzen J, Healy H. Biology and relevance of C-reactive protein in cardiovascular and renal disease. Ann Clin Lab Sci. 2000; 30: 133–143.
  2. Makayama, T. et al. (1993) Clinical Chemistry. 39(2): 293-297.
  3. Du Clos TW. Function of C-reactive protein. Ann Med. 2000; 32: 274–278.
  4. Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol. 1996; 156: 4815–4820.
  5. Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun. 2001; 69: 1747–1754.
  6. Yasojima K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001; 158: 1039–1051.
  7. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000; 20: 2094–2099.
  8. Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 2000; 10: 435–451.
  9. Mendall MA, Patel P, Ballam L, et al. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J. 1996; 312: 1061–1065.
  10. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–979.
  11. Tomoda H, Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J. 2000; 140: 324–328.
  12. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina Refractory to standard treatment trial. J Am Coll Cardiol. 2000; 35: 1535–1542.
  13. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994; 331: 417–424.
  14. Festa A, D’Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102: 42–47.
  15. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999; 282: 2131–2135.
  16. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286: 327–334.
  17. Tchernof A, Nolan A, Sites CK, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002; 105: 564–569.
Code CY-8071
Product Type ELISA Kit
Size 96 Assays
Application ELISA

Related Content:

Pathway Posters

AMPK Pathway

Pathway Posters


Pathway Posters

Regulation of eIF4E